Of these 745 participants, 468 (62.8%) underwent MRI and prostate biopsy; prostate cancer was detected in 187 participants (40.0%). The median age at diagnosis was 64 years (range, 57 to 73).

Of these participants, 62.8% underwent MRI and prostate biopsy. Median age at diagnosis was 64. The authors acknowledged several limitations to the study -- primarily the fact that participation ...

A false-positive test result may create anxiety and lead to additional medical procedures, such as a prostate biopsy, that can be harmful. False-positive test results are common with PSA screening ...

TRANSPERINEAL (TP) prostate biopsy is a promising alternative to the traditional transrectal (TR) biopsy for prostate cancer (PCa) diagnosis. As PCa detection remains a challenge, the ability of these ...

Additional experience will be needed to decipher whether 18F-FMAU PET/CT adds distinctive value to mpMRI in localizing clinically significant prostate cancer. Moreover, the potential diagnostic ...

CALGARY, AB, April 1, 2025 /CNW/ - OncoHelix, a leader in precision diagnostics, is proud to announce its partnership with AstraZeneca Canada to deliver cutting-edge liquid biopsy testing for men with ...

A trial found no meaningful difference in detection of clinically significantly prostate cancer between multiparametric MRI-based and microultrasound-based biopsy techniques. Microultrasonography ...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this ...

This multicentre, open-label, randomised, non-inferiority trial across eight countries, conducted from 2021 to 2024, included biopsy-naive adult men with clinical suspicion of prostate cancer due ...

FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with ... a randomized, multicenter, open-label trial which evaluated 468 ...